SEC Filing Summary

On July 14-16, 2026, Vivo Opportunity, LLC and its affiliated entities (Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman, LLC, and Vivo Opportunity Cayman Fund, L.P.) reported the acquisition of InMed Pharmaceuticals Inc. common shares. These transactions, classified under Form 4 filing with transaction code "P" (purchase) and acquisition code "A", involved a total of 19,246 shares purchased at a price of $1.55 per share. The reporting owners, who are ten percent owners, acquired these shares indirectly. Vivo Opportunity, LLC, as the general partner, disclaims beneficial ownership beyond its pecuniary interest. The transactions resulted in increased post-transaction shareholdings for the respective entities, with Vivo Opportunity Fund Holdings, L.P. holding 743,057 shares and Vivo Opportunity Cayman Fund, L.P. holding 75,019 shares after these acquisitions.